Fetal Intrauterine Transfusion for Anemia: Technique and Outcomes

Fetal anemia can progress silently while causing high-output cardiac failure, hydrops fetalis, neurological injury, or fetal death. Intrauterine transfusion (IUT) has transformed care for severe anemia by correcting the oxygen-carrying deficit before birth and allowing the pregnancy to continue toward a safer gestational age.

The procedure requires careful screening, expert ultrasound guidance, suitable blood products, and coordinated maternal-fetal and neonatal care. Its use is most established in red-cell alloimmunization, although parvovirus B19 infection, fetomaternal hemorrhage, twin complications, and inherited hematologic disorders may also lead to profound fetal anemia.

The subject fits within the wider perinatal medicine interests represented by the FAOPS 2020 congress, which brought together specialists in fetal, neonatal, and maternal care. Current practice combines Doppler surveillance with individualized procedural planning rather than relying on fetal anemia symptoms, since many affected fetuses show no obvious clinical signs until disease is advanced.

Why Fetal Anemia Requires Early Action

The fetal circulation responds to anemia by increasing cardiac output. Blood flow is redirected toward vital organs, while the heart works harder to maintain oxygen delivery. When compensation fails, venous congestion and reduced oncotic pressure can produce ascites, pleural or pericardial effusion, skin edema, and placentomegaly. This condition, known as hydrops fetalis, is associated with a higher risk of procedural complications and poor perinatal outcomes.

Maternal red-cell antibodies remain a major cause in many settings. Anti-D disease has become less common where prophylaxis is effective, but anti-c and anti-Kell alloimmunization can cause serious disease. Parvovirus B19 suppresses fetal erythropoiesis, while massive fetomaternal hemorrhage removes circulating fetal blood. Other causes include alpha-thalassemia major, congenital infection, placental tumors, and complications of monochorionic twin pregnancy.

The maternal antibody history and previous pregnancy outcomes help define risk, but they do not measure current fetal anemia. Serial ultrasound is therefore essential. Middle cerebral artery peak systolic velocity (MCA-PSV), expressed in multiples of the median for gestational age, is the standard noninvasive screening method. A value around 1.5 MoM or higher raises concern and generally prompts referral for specialist assessment, although gestational age, technical quality, and the cause of anemia must be considered.

Selecting Candidates for Transfusion

MCA Doppler is a screening test rather than a direct hemoglobin measurement. False-positive results become more frequent later in pregnancy, and fetal movement, angle of insonation, and operator experience affect accuracy. When results are abnormal, the fetus should be assessed for hydrops, cardiac function, growth, amniotic fluid abnormalities, and evidence of placental or infectious disease.

Cordocentesis provides a direct fetal blood sample and allows confirmation of hemoglobin, hematocrit, blood type, and relevant laboratory findings. In many cases, diagnostic sampling and transfusion are performed during the same procedure so that a severely anemic fetus is not exposed to two separate needle interventions. The decision depends on the Doppler trend, antibody type, gestational age, clinical findings, and the experience of the fetal therapy unit.

Referral should occur before hydrops develops whenever severe anemia is likely. A fetus with significant anemia but preserved cardiac function usually has a better chance of recovery than one with advanced hydrops. Counseling should cover the need for repeated transfusions, possible hospitalization, preterm delivery, fetal loss, and neonatal intensive care.

How The Procedure Is Performed

IUT is conducted in a specialist fetal medicine center under continuous ultrasound guidance. Maternal preparation commonly includes blood tests, informed consent, assessment of infection risk, and medication according to local anesthesia and procedural protocols. Fetal analgesia or immobilization may be used when clinically appropriate. Maternal position, placental location, amniotic fluid volume, and fetal presentation influence the safest needle route.

The preferred access point is often the umbilical vein near its placental insertion, where the cord is relatively stable and the vessel is accessible. In other circumstances, transfusion may be performed into the intrahepatic umbilical vein or, less commonly, the fetal peritoneal cavity. The operator first obtains a fetal blood sample, measures the starting hematocrit, and then slowly administers compatible donor red cells while monitoring the fetal heart rate and venous circulation.

The volume is calculated from the estimated fetal weight, initial hematocrit, donor-unit hematocrit, and desired final hematocrit. Packed red cells are typically selected to be compatible with maternal antibodies and specially prepared, often including leukoreduction, irradiation, and cytomegalovirus-safe processing according to institutional policy. The goal is to correct oxygen-carrying capacity without causing sudden circulatory overload.

The transfusion may need to be repeated because donor red cells gradually age and maternal antibodies continue to destroy susceptible cells. Intervals vary, but many pregnancies require procedures every two to four weeks, with shorter intervals early in treatment or in rapidly progressive disease. The final transfusion and timing of birth are planned around fetal response, gestational age, and neonatal resources.

Outcomes And Factors That Shape Them

Survival after IUT for red-cell alloimmunization is high in experienced centers, especially when treatment begins before hydrops. Many non-hydropic fetuses have survival rates above 90 percent in published specialist series. Outcomes are less favorable when severe hydrops, extreme prematurity, cardiac dysfunction, or profound anemia is present at the first procedure.

Correction of anemia often improves hydrops over days to weeks, although fluid collections can persist after the hematocrit normalizes. Neurological outcomes are generally favorable when hypoxia has been avoided, but severe fetal anemia can cause brain injury before treatment. Long-term follow-up is particularly important for pregnancies complicated by hydrops, repeated fetal compromise, or very early delivery.

The underlying cause influences recurrence and neonatal management. Alloimmune disease may require phototherapy, intravenous immunoglobulin, exchange transfusion, or simple transfusion after birth. Parvovirus-related anemia usually resolves as erythropoiesis recovers, while congenital hemoglobin disorders require specialist hematology care. Neonatal assessment should be planned before delivery, with blood products and intensive care available when needed.

Perinatal care also includes screening for conditions that can produce hypoxemia after birth. For example, clinicians can review the role of pulse oximetry screening when planning broader newborn surveillance, although oxygen saturation screening does not diagnose fetal anemia and cannot replace antenatal Doppler or fetal blood assessment.

Risks And Safety Considerations

The principal immediate risk is a transient or persistent fetal bradycardia. Other complications include cord hematoma, vessel spasm, bleeding, fetal-maternal hemorrhage, infection, rupture of membranes, preterm labor, and accidental needle injury. Rarely, the transfusion can cause fetal exsanguination, acute cardiac decompensation, or death. Risk depends on gestational age, fetal condition, placental position, operator expertise, and the number of needle passes.

Hydropic fetuses may be technically more difficult to treat because edema can impair cardiac function and make the fetus less tolerant of changes in blood volume. A very low starting hematocrit also requires careful correction. Slow administration, repeated ultrasound checks, and attention to the fetal heart rate help reduce hemodynamic stress.

Maternal complications are uncommon but should be discussed. Fetomaternal hemorrhage can increase maternal sensitization, particularly if an antigen-positive fetus is exposed to maternal circulation. Anti-D immunoglobulin and other preventive measures are managed according to maternal blood type, antibody profile, and local guidelines. A documented emergency plan is important if bleeding, contractions, or reduced fetal movement occurs after the procedure.

Coordinating Care Before And After Birth

IUT is most successful when the fetal therapy team, transfusion laboratory, obstetric unit, anesthetic service, and neonatal team communicate early. Blood should be reserved before the procedure, and compatibility testing must account for maternal antibodies because these antibodies cross the placenta and can affect the fetus and newborn.

After treatment, serial MCA-PSV measurements must be interpreted carefully. Transfused adult red cells alter fetal blood flow characteristics, so Doppler values may become less reliable as a direct indicator of hemoglobin. Clinical examination, ultrasound findings, timing since the last transfusion, and previous hematocrit values all contribute to the follow-up decision.

Delivery is not automatically indicated immediately after anemia is corrected. Continuing the pregnancy may reduce prematurity-related illness, while delivery becomes more appropriate when fetal deterioration, recurrent anemia that cannot be safely treated, obstetric complications, or adequate maturity changes the balance. A neonatal team should be present for birth when significant hemolysis, hydrops, or respiratory compromise is expected.

Care teams can use these principles when building a local pathway:

• Refer suspected severe fetal anemia to a specialist fetal medicine center without delay.
• Use serial MCA-PSV Doppler alongside antibody history and ultrasound assessment.
• Confirm blood-product compatibility and procedural calculations before needle placement.
• Plan repeat transfusions, corticosteroid timing, delivery, and neonatal support together.
• Record maternal antibodies and fetal treatment history clearly for newborn clinicians.

Effective management depends on recognizing anemia before irreversible injury occurs and matching intervention to the fetus’s condition. Clinicians and researchers can use the FAOPS archive as a gateway to broader perinatal medicine resources, while specialist centers continue refining Doppler thresholds, transfusion practice, and long-term follow-up. Early referral, meticulous technique, and coordinated neonatal planning give affected pregnancies the strongest opportunity for a safe birth and healthy development.